Project Grant R01CA299475
Award Date
5/1/25
Completion Date
4/30/30
Dollars Obligated
$753K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the PREDICT (Personalized Risk-Based Follow-Up of Cervical Cancer Screening in Practice) project. The $723,513 award, granted on June 10, 2024, supports the development, testing, and dissemination of a health IT-enabled, multilevel intervention to promote personalized,...
The National Cancer Institute (NCI) awarded a 5-year, $171,989 Project Grant (CFDA 93.398 Cancer Research Manpower) to the University of Florida (UF) to prevent cervical cancer among women with chronic conditions and social vulnerability. The project, titled "Preventing Cervical Cancer Through HPV Self-Collection and Patient Navigation Among Women Living with Chronic Conditions and Social Vulnerability," aims to adapt an evidence-based cervical cancer prevention intervention for this...
The National Cancer Institute (NCI) awarded a $176,534 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Oregon Health & Science University (OHSU) for the period of August 1, 2024 to July 31, 2029. The primary objectives of this grant are to: 1) Describe cervical cancer screening rates among middle to older age Mexican immigrants in a network of community health centers (CHCs) from 2012-2023; 2) Examine individual, organizational, and structural factors impacting...
The National Cancer Institute (NCI) awarded a $643,363 Cooperative Agreement under the Cancer Cause and Prevention Research (CFDA 93.393) program to Tulane University. The project, titled "A Hybrid Type III Effectiveness-Implementation, Pragmatic Intervention Trial for Cervical Cancer Screen and Treat in Mozambique," will test implementation best practices for deploying a screen and treat approach to cervical cancer screening utilizing self-collected HPV DNA testing within HIV care and...
This federal Cooperative Agreement award, totaling $706,365.00, was issued by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program. The award aims to implement the World Health Organization-endorsed "screen, triage, and treat" (ISTAR) approach for cervical cancer screening among women living with HIV in La Romana, Dominican Republic. The project seeks to address barriers to adoption, integration, and sustainability of evidence-based...
The National Cancer Institute (NCI) awarded a $300,374 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The University of South Dakota (USD) to develop and test the efficacy of a mobile web app intervention aimed at increasing cervical cancer screening rates among indigenous women in the Yankton Sioux Tribe reservation in South Dakota. The 4-year project will involve a randomized controlled trial to evaluate the feasibility and impact of the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $547,047 to Georgetown University to test a bundled multicancer screening and genetic services navigation program to improve cancer health equity among non-Hispanic Black and Hispanic women. The 5-year project aims to address patient- and organization-level barriers to cancer screening and genetic testing, which disproportionately impact these populations and...
The National Cancer Institute (NCI) awarded a $3,942,082 Cooperative Agreement titled "The Mass Partnership for Community-Engaged Cancer Control Equity" to the Harvard T.H. Chan School of Public Health under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program. This 5-year award aims to advance cancer control equity by strengthening the capacity of community health centers (CHCs) to deliver evidence-based cancer screening and tobacco treatment services, while...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $368,070 to conduct research to identify and address barriers in the cervical cancer treatment cascade among women with HIV in South Africa. The research aims to investigate factors that negatively impact follow-up appointment attendance and engagement with necessary cervical cancer treatment for women with HIV, in order to develop a tailored intervention to improve...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), aims to develop enhanced cancer risk prediction models for underrepresented populations, particularly Black and Hispanic individuals. The $432,304 grant, awarded on January 3, 2025, will fund the development of novel data integration and machine learning methods to effectively leverage multi-source electronic health record (EHR) and biobank data. The...